eLibrary
  • Home
  • Sources
  • Search
  • About

A Comparative Study on the Mechanisms and Therapeutic Efficacy of Common Natural Products and Their Derivatives in the Treating Metabolic Dysfunction Associated Steatohepatitis

Yuhang Liu
World Scientific Research Journal, (2026), Vol.12, No.9, pp.70-78
Published: September 15, 2026
DOI: 10.6911/WSRJ.202609_12(9).0008
PDF: Download Full Text PDF
Abstract

MASH is a chronic liver disease with high global prevalence, which has become a major driver of cirrhosis and liver cancer. This study addresses the limitation that most existing research focuses on individual compounds, so four natural products, which are curcumin, silybin, tanshinone IIA, and Lycium barbarum polysaccharide (LBP), were selected based on their extensive documentation and structural diversity. The main goal was to systematically compare their mechanisms of action and clinical effectiveness against MASH. Peer-reviewed articles published between 2020 and 2026 were systematically retrieved and screened according to predefined quality criteria to build an evaluation framework. Then, the analysis examined four main areas: lipid regulation, anti-inflammation, antioxidant activity, and anti-fibrosis work. Data synthesis was performed through systematic cross-comparison of included studies. The results show that the curcumin phospholipid complex called Meriva is the most promising candidate. We put forward a few different combination treatment plans because their individual ways of working might complement each other and make the total effect better than any single one. By doing all of this work, it fills a gap that existed in past systematic studies of natural products for MASH and a scientific basis for precision medicine and drug development is provided.

Keywords: Metabolic dysfunction associated steatohepatitis; MASH; natural products; derivatives.
APA Citation: Yuhang Liu (2026). A Comparative Study on the Mechanisms and Therapeutic Efficacy of Common Natural Products and Their Derivatives in the Treating Metabolic Dysfunction Associated Steatohepatitis. World Scientific Research Journal, 12(9), 70-78. https://doi.org/10.6911/WSRJ.202609_12(9).0008

References

  1. Aggarwal, B. B., & Sung, B. (2024). Efficacy of curcumin phospholipid in non-alcoholic steatohepatitis: A phase II randomized controlled trial. Phytomedicine, 121, 154892. https://doi.org/10.1016/j.phytomed.2024.154892.
  2. Yaikwawong, M., & others. (2025). Curcumin for MASH in type 2 diabetes. Nutrients, 17, 1972. https://doi.org/10.3390/nu17111972
  3. Chuengsam, S., & others. (2025). Curcumin attenuates liver fat in obese patients. International Journal of Molecular Sciences, 26, 9286. https://doi.org/10.3390/ijms26209286
  4. Li, J., & others. (2024). Sodium tanshinone IIA sulfonate attenuates NASH via SREBP-1c/FAS pathway. Chinese Pharmacological Bulletin, 40, 789–796.
  5. Wang, X., & others. (2025). Tanshinone IIA sulfonate activates PPARα/PGC-1α in MASH. Pharmacological Research, 201, 107345. https://doi.org/10.1016/j.phrs.2025.107345
  6. Wang, L., & others. (2024). Selenylated Lycium barbarum polysaccharide ameliorates NASH via gut-liver axis. Food & Function, 15, 2890–2901. https://doi.org/10.1039/D3FO02246A
  7. Peng, S., & others. (2025). Tetrahydrocurcumin improves MASH via gut microbiota. International Journal of Molecular Sciences, 26, 895. https://doi.org/10.3390/ijms26040895
  8. Mencarelli, A., & others. (2024). Silybin phospholipid complex improves liver function in NASH patients: A multicenter randomized trial. Hepatology Communications, 8, e02218. https://doi.org/10.1002/hep4.2218
  9. Boonloh, K., & others. (2025). THU/ALK-5i suppresses MASH progression. Scientific Reports, 15, 39936. https://doi.org/10.1038/s41598-025-94562-3
  10. Zhang, Y., & others. (2025). Silybin improves MASH via gut-bile acid-FXR axis. Journal of Hepatology, 82, 456–470. https://doi.org/10.1016/j.jhep.2024.10.012
  11. Kim, H. J., & others. (2023). Curcumin analog C66 ameliorates NASH by inhibiting JNK pathway. Journal of Ethnopharmacology, 312, 116892. https://doi.org/10.1016/j.jep.2023.116892
  12. Liu, C., & others. (2023). Tanshinone IIA ameliorates NASH via NF-κB and TGF-β1 pathways. Phytomedicine, 109, 154231. https://doi.org/10.1016/j.phytomed.2023.154231
  13. Ma, J. M., Li, D. D., Li, M. J., & others. (2024). Lycium barbarum polysaccharide combined with aerobic exercise ameliorates NASH via AMPK/PPARα/PGC-1α pathway. Journal of Ethnopharmacology, 318, 116876. https://doi.org/10.1016/j.jep.2024.116876
  14. Lin, X., Zeng, Y., Ning, J., & others. (2024). Nicotinate-curcumin inhibits AKR1B10/ACCα pathway. Lipids in Health and Disease, 23, 201. https://doi.org/10.1186/s12944-024-02196-2
  15. Yang, L. C., Wang, C. C., Lee, D. Y., & others. (2024). 4,4-Diallyl curcumin bis(2,2-hydroxymethyl)propanoate ameliorates nonalcoholic steatohepatitis in mouse models. Chemical Biology & Drug Design, 103, e14532. https://doi.org/10.1111/cbdd.14532
  16. Cunningham, R. P., Moore, M. P., Moore, A. N., & others. (2018). Curcumin mitigates NASH in female Wistar rats. Physiological Reports, 6, e13789. https://doi.org/10.14814/phy2.13789
  17. Zhang, J., & others. (2023). Silybin inhibits succinate/GPR91 pathway to reverse liver fibrosis. Acta Pharmacologica Sinica, 44, 1567–1578. https://doi.org/10.1038/s41401-023-01087-1
  18. Zhao, J., & others. (2023). Tanshinone I suppresses NLRP3 inflammasome. Molecular Medicine, 29, 84. https://doi.org/10.1186/s10020-023-00687-1
  19. Musso, G., Cassader, M., Paschetta, E., & others. (2025). Phospholipid curcumin Meriva in nonalcoholic steatohepatitis: A randomized trial. Hepatology, 81, 560–575. https://doi.org/10.1002/hep.33647
  20. Cai, Z., Deng, T., Wei, N, & others. (2023). Silybin ameliorates NASH lipid metabolism in mice. Chinese Journal of Clinical Pharmacology and Therapeutics, 28, 241–248.
  21. Suguro, R., Pang, X. C., Yuan, Z. W., & others. (2020). Silybin plus tangeretin attenuates NASH via lipid modulation. Pharmacological Research, 151, 104519. https://doi.org/10.1016/j.phrs.2019.104519
  22. Loguercio, C., & others. (2025). Long-term effect of silybin-phospholipid complex in NASH. Liver International, 45, e15932. https://doi.org/10.1111/liv.15932
  23. Liu, X. (2024). Mechanism of tanshinone IIA in NASH via NETs and hepatocyte apoptosis [Doctoral dissertation].
  24. Zhang, H., & others. (2024). Network pharmacology of tanshinone IIA in MASH. Phytomedicine, 128, 155482. https://doi.org/10.1016/j.phytomed.2024.155482
  25. Li, D.-D., & others. (2024). LBP combined with exercise improves NASH via AMPK pathway. Journal of Ethnopharmacology, 318, 116876. https://doi.org/10.1016/j.jep.2024.116876
  26. Kim, J. K., & others. (2020). Tanshinone I inhibits NLRP3 inflammasome. Biochemical Pharmacology, 178, 114093. https://doi.org/10.1016/j.bcp.2020.114093
  27. Wah Kheong, C., Nik Mustapha, N. R., & Mahadeva, S. (2017). Randomized trial of silymarin in NASH. Clinical Gastroenterology and Hepatology, 15, 1940–1949. https://doi.org/10.1016/j.cgh.2017.06.033
  28. Zhang, B., Xu, D., She, L., & others. (2018). Silybin inhibits NLRP3 inflammasome via NAD+/SIRT2. FASEB Journal, 32, 757–767. https://doi.org/10.1096/fj.201700468R
  29. Amagase, H., & Farnsworth, N. R. (2011). Lycium barbarum (Goji): A review. Food Research International, 44, 1702–1717. https://doi.org/10.1016/j.foodres.2011.03.027
  30. Zhang, J., & others. (2023). Silybin inhibits succinate/GPR91 pathway in liver fibrosis. Acta Pharmacologica Sinica, 44, 1567–1578. https://doi.org/10.1038/s41401-023-01087-1
  31. Li, S., & others. (2024). Tanshinone IIA modulates NETs and hepatocyte apoptosis in NASH. International Immunopharmacology, 125, 111256. https://doi.org/10.1016/j.intimp.2024.111256
  32. Zhong, S., & others. (2023). Efficacy and safety of silymarin in NAFLD: A meta-analysis. European Journal of Gastroenterology & Hepatology, 35, 412–420. https://doi.org/10.1097/MEG.0000000000002465
  33. Carmela, C., Andreone, P., Brisc, C., & others. (2012). Silybin plus vitamin E in NAFLD. Free Radical Biology and Medicine, 52, 1658–1665. https://doi.org/10.1016/j.freeradbiomed.2012.01.032
  34. Xiao, T., Shen, Y., & Zhou, M. (2025). Efficacy of Yunpi Jiangzhi decoction combined with silymarin. World Clinical Drugs, 46, 55–59.
  35. Yang, J., & others. (2021). Curcumin ameliorates NASH via hepatic endothelial function improvement. Journal of Agricultural and Food Chemistry, 69, 7965–7977. https://doi.org/10.1021/acs.jafc.1c01234
  36. Mirhafez, S. R., & others. (2021). Curcumin phytosome in NAFLD: A trial. Advances in Experimental Medicine and Biology, 1308, 295–304. https://doi.org/10.1007/978-3-030-64716-8_21
  37. Zhang, Y., & others. (2021). Nicotinate-curcumin improves NASH via lipid metabolism. Frontiers in Pharmacology, 12, 756294. https://doi.org/10.3389/fphar.2021.756294
  38. Lin, X., & others. (2024). Nicotinate-curcumin inhibits triglyceride synthesis. Lipids in Health and Disease, 23, 201. https://doi.org/10.1186/s12944-024-02196-2
  39. Gao, L. L., & others. (2021). Lycium barbarum polysaccharide for NAFLD: A trial protocol. Trials, 22, 566. https://doi.org/10.1186/s13063-021-05524-0
  40. Esmaeli, M., Dehabadi, M. D., & Ghanbari, A. (2025). Curcumin in hepatocellular carcinoma: A review. Cancer Cell International, 25, 335. https://doi.org/10.1186/s12935-025-04120-1
  41. Gao, L. L., & others. (2024). LBP improves gut microbiota in MASH patients. Clinical Nutrition, 43, 1876–1888. https://doi.org/10.1016/j.clnu.2024.06.015
  42. Gerami, H., & others. (2026). Nanocurcumin for NAFLD fibrosis: A trial protocol. BMC Nutrition, 12, 45. https://doi.org/10.1186/s40795-026-00789-2
  43. Wu, J., & others. (2023). Silybin regulates P450 in NAFLD. Acta Pharmacologica Sinica, 44, 133–144. https://doi.org/10.1038/s41401-022-01004-9
© 2026 eLibrary · Stand on the shoulders of giants